autologous anti-MSLN CAR/HLA-A*02-gated inhibitory receptor/B2M shRNA-expressing T lymphocytes A2B694
Term · Oncology and biomedicine · MLC-T-ONC-011480
A preparation of autologous T lymphocytes that have been transduced with a lentiviral vector expressing an activating chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) mesothelin (MSLN), a leukocyte immunoglobulin-like receptor 1 (LIR-1)-based inhibitory receptor specific for human leukocyte antigen (HLA)-A*02 (HLA-A*02), and a short hairpin RNA (shRNA) targeting beta-2 microglobulin (B2M; beta2M), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MSLN CAR/HLA-A*02-gated inhibitory receptor/B2M shRNA-expressing T lymphocytes A2B694 target and bind to MSLN-expressing tumor cells, thereby killing MSLN-expressing tumor cells that have loss of heterozygosity (LOH) for HLA-A*02 protein. The inhibitory receptor specific for HLA-A*02 acts as a self-regulated safety switch that blocks the killing of HLA-A*02-positive MSLN-expressing normal, healthy cells. HLA-A*02 is expressed on normal cells but not on tumor cells due to LOH. The B2M shRNA disrupts the expression of the B2M component of the HLA class I molecule. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.
| Identifier | MLC-T-ONC-011480 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | autologous anti-MSLN CAR T cells A2B694; autologous anti-MSLN logic-gated CAR T cells A2B694; autologous anti-MSLN logic-gated Tmod CAR T cells A2B694; autologous MSLN-directed logic-gated CAR-T cells A2B694; autologous Tmod CAR T cells A2B694; Tmod CAR-T cells A2B694 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-011480",
"term": "autologous anti-MSLN CAR/HLA-A*02-gated inhibitory receptor/B2M shRNA-expressing T lymphocytes A2B694",
"field": "Oncology and biomedicine",
"definition": "A preparation of autologous T lymphocytes that have been transduced with a lentiviral vector expressing an activating chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) mesothelin (MSLN), a leukocyte immunoglobulin-like receptor 1 (LIR-1)-based inhibitory receptor specific for human leukocyte antigen (HLA)-A*02 (HLA-A*02), and a short hairpin RNA (shRNA) targeting beta-2 microglobulin (B2M; beta2M), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MSLN CAR/HLA-A*02-gated inhibitory receptor/B2M shRNA-expressing T lymphocytes A2B694 target and bind to MSLN-expressing tumor cells, thereby killing MSLN-expressing tumor cells that have loss of heterozygosity (LOH) for HLA-A*02 protein. The inhibitory receptor specific for HLA-A*02 acts as a self-regulated safety switch that blocks the killing of HLA-A*02-positive MSLN-expressing normal, healthy cells. HLA-A*02 is expressed on normal cells but not on tumor cells due to LOH. The B2M shRNA disrupts the expression of the B2M component of the HLA class I molecule. MSLN, a cell surface glycoprotein involved in cell adhesion, is overexpressed in a variety of cancer cell types.",
"synonyms": [
"autologous anti-MSLN CAR T cells A2B694",
"autologous anti-MSLN logic-gated CAR T cells A2B694",
"autologous anti-MSLN logic-gated Tmod CAR T cells A2B694",
"autologous MSLN-directed logic-gated CAR-T cells A2B694",
"autologous Tmod CAR T cells A2B694",
"Tmod CAR-T cells A2B694"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/autologous-anti-msln-car-hla-a-02-gated-inhibitory-receptor-b2m-shrna-expressing/"
}
Record 2,812 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.